Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes - PubMed

8 days ago

Lecanemab is an antibody targeting Aβ-protofibrils and plaque, showing delay in disease progression in early Alzheimer's Disease (AD).
The study focused on ApoE ε4 non-carriers or heterozygotes, representing 85% of the 1795 participants in the Clarity AD trial.
Significant reduction in clinical decline was observed on CDR-SB at 18 months compared to placebo in the ApoE ε4 subgroup.
Amyloid PET, ADAS-Cog14, ADCS-MCI-ADL, and HRQoL results supported the efficacy of lecanemab.
Common adverse reactions included infusion-related reactions (26%), ARIA-H (13%), fall (11%), headache (11%), and ARIA-E (9%).
Continued benefit was observed through 36 months in the open-label extension phase, with a 28% reduced risk of progression to the next AD stage.
Early treatment initiation showed a disease-modifying effect, with delayed start results not catching up to early start results.
The study confirms lecanemab's potential in slowing disease progression and reducing amyloid markers in ApoE ε4 non-carriers or heterozygotes.

Hasty Briefsbeta